Syringe Services Programs Face Federal Funding Cuts Despite 30 Years of Evidence

Syringe services programs, which have operated in the United States for nearly three decades with substantial evidence of effectiveness, are confronting new federal funding restrictions that threaten their ability to deliver comprehensive harm reduction services. The Substance Abuse and Mental Health Services Administration issued updated guidance in April 2026 that narrows what federal grant dollars may support at these programs, eliminating reimbursement for supplies and services that had been eligible under previous administrations.

What three decades of research demonstrates

The evidence base supporting syringe services programs ranks among the most settled in drug policy research. According to the Centers for Disease Control and Prevention, nearly 30 years of studies show these programs are safe, effective, and cost-saving, and crucially, they do not increase illegal drug use or crime in the communities where they operate.

The quantitative findings are substantial. Use of a syringe services program is associated with an estimated 50 percent reduction in HIV and hepatitis C incidence among people who inject drugs. When these programs are combined with medication for opioid use disorder, the reduction in infectious disease transmission exceeds two-thirds. Participants in syringe programs are approximately five times more likely to enter drug treatment and about three times more likely to stop or reduce injecting than individuals who do not participate.

On the two objections most commonly raised at local hearings, the research consistently fails to support either claim. Program presence has not been found to increase neighborhood crime rates, nor has it been associated with increases in unsafe syringe disposal. The fiscal case is equally compelling: a single course of hepatitis C treatment costs far more than a year of supplies for one program participant.

Current program landscape

As of March 2025, 37 states and the District of Columbia had laws explicitly or implicitly authorizing syringe services programs. More than 550 programs were operating across 45 states, the District of Columbia, and Puerto Rico, including 25 mobile units designed to reach rural and underserved areas.

Five states had no operating program at all: Kansas, Mississippi, Nebraska, South Dakota, and Wyoming. Seven states require participants to register, a condition that research on program uptake generally treats as a deterrent to the populations hardest to reach. Registration requirements are a state-level policy choice rather than a federal condition, meaning they persist regardless of changes in federal funding guidance.

The April 2026 funding restrictions

Federal money has never directly paid for syringes themselves. A ban ran from 1988 until partial changes in 2015 and 2016, and even after those changes federal dollars could support staff, vans, counseling, and referrals but not the syringes. The April 2026 guidance extended the exclusion to several additional items that had been eligible under the previous administration.

Federal grant funds may no longer be used for fentanyl test strips, sterile water, saline, ascorbic acid, safer smoking supplies, or overdose hotlines. The guidance built on direction issued in July 2025 under an executive order. The fentanyl test strip change carries particular consequence because CDC and SAMHSA had specifically permitted federal funds to be used for test strips beginning in 2021 and had described drug checking as an evidence-based strategy. Programs that built test strip distribution on federal grants must now identify alternative funding sources to maintain this service.

Several items remain eligible for federal support: naloxone and nalmefene, lockboxes, sharps disposal containers, wound care supplies, FDA-approved home test kits for HIV and hepatitis, navigation for HIV prevention medication, and condoms.

The volatile funding environment

The April 2026 guidance arrives during a period of unusual volatility in federal harm reduction funding. In January 2026, an attempt to terminate nearly two billion dollars in SAMHSA discretionary grants was reversed within 24 hours following congressional pushback. Staffing reductions at SAMHSA have reduced agency capacity by roughly half, further complicating grant administration and oversight.

For local program operators, the practical implication is that federal grant conditions have become a live variable in service availability rather than a fixed background. A program's supply list can change without any change in state law or local approval, forcing providers to seek alternative funding streams or reduce services.

What persuades skeptical officials

Anyone who has attended county commission hearings on syringe program proposals will recognize the gap between the research summarized in CDC publications and the arguments that dominate local debate. Opposition is typically organized around two claims: that a program will attract drug use to the area, and that it will leave syringes in parks and public spaces. Neither claim is supported by the research literature.

What tends to persuade officials who begin skeptical is not epidemiological data but the fiscal case and the referral function. The treatment referral figures give programs a defensible answer to the objection that they enable use rather than interrupt it. Programs function as an entry point to treatment rather than an alternative to it, a framing that resonates with officials concerned about reducing the visible presence of untreated substance use in their jurisdictions.

People seeking help for opioid use disorder can find medication-assisted treatment programs nationwide. For those in crisis, the 988 Suicide and Crisis Lifeline provides immediate support.